Zhengye Biotechnology Holding Limited (ZYBT)
NASDAQ: ZYBT · Real-Time Price · USD
4.280
-0.050 (-1.15%)
Feb 11, 2025, 2:24 PM EST - Market open

ZYBT Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2023 FY 2022 FY 2021
Period Ending
Jun '24 Dec '23 Dec '22 Dec '21
Revenue
189.75211.65260.27214.07
Revenue Growth (YoY)
-25.23%-18.68%21.58%-
Cost of Revenue
84.4291.84107.2789.45
Gross Profit
105.33119.81153124.62
Selling, General & Admin
66.9166.6363.5658.86
Research & Development
11.1911.913.4211.37
Operating Expenses
74.7574.8286.7272.16
Operating Income
30.5844.9966.2852.47
Interest Expense
-4.32-4.42-2.84-1.05
Interest & Investment Income
0.420.310.110.11
Other Non Operating Income (Expenses)
3.052.890.811.62
EBT Excluding Unusual Items
29.7243.7664.3653.15
Asset Writedown
---0.45-0.08
Pretax Income
29.7243.7663.9153.07
Income Tax Expense
5.566.258.176.6
Earnings From Continuing Operations
24.1637.5155.7446.47
Minority Interest in Earnings
-3.88-6.05-9.01-7.51
Net Income
20.2931.4646.7438.96
Net Income to Common
20.2931.4646.7438.96
Net Income Growth
-53.70%-32.69%19.96%-
Shares Outstanding (Basic)
46464646
Shares Outstanding (Diluted)
46464646
EPS (Basic)
0.440.691.020.85
EPS (Diluted)
0.440.691.020.85
EPS Growth
-53.70%-32.69%19.96%-
Free Cash Flow
46.940.79-9.9912.75
Free Cash Flow Per Share
1.030.89-0.220.28
Gross Margin
55.51%56.61%58.78%58.22%
Operating Margin
16.11%21.25%25.47%24.51%
Profit Margin
10.69%14.86%17.96%18.20%
Free Cash Flow Margin
24.72%19.27%-3.84%5.95%
EBITDA
53.968.985.0868.48
EBITDA Margin
28.41%32.55%32.69%31.99%
D&A For EBITDA
23.3223.9118.816.01
EBIT
30.5844.9966.2852.47
EBIT Margin
16.11%21.25%25.47%24.51%
Effective Tax Rate
18.69%14.29%12.79%12.44%
Advertising Expenses
-2.542.582.23
Source: S&P Capital IQ. Standard template. Financial Sources.